

Overview of the clinical trials that led to the authorisation of monoclonal antibody therapies in the EU

Workshop "Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants"





Monoclonal antibodies authorised in EU for the treatment and/or prevention of COVID-19

Medicine		
Regdanvimab Regkirona	Treatment	November 2021
Casirivimab/Imdevimab <i>Ronapreve</i>	Pre- and post-exposure prophylaxis Treatment	November 2021
Sotrovimab Xevudy	Treatment	December 2021
Tixagevimab/Cilgavimab Evusheld	Pre-exposure prophylaxis Treatment	March 2022 September 2022



Monoclonal antibodies that received a recommendation according under Art.5(3)

Medicine	Indication	
Bamlanivimab/Etesevimab	Treatment	March 2021
Regdanvimab	Treatment	March 2021
Sotrovimab	Treatment	May 2021
Casirivimab/Imdevimab	Treatment	February 2021

Not licensed in EU - with a previous EUA in US (currently not authorised)

Bebtelovimab for treatment of COVID-19



Pre- and post-exposure prophylaxis

Product	Indication		Posology
Casirivimab/Imdevimab	Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg		 Post-exp: 600+600 mg IV/SC Pre-exp: 600+600 mg IV/SC, 300+300 mg q4w
Tixagevimab/Cilgavimab	Pre-exposure prophylaxis of COVID adolescents	0-19 in adults and	300+300 mg IM

Pre- and post-exposure prophylaxis

Product	Indication		Posology
Casirivimab/Imdevimab	Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg		 Post-exp: 600+600 mg IV/SC Pre-exp: 600+600 mg IV/SC, 300+300 mg q4w
-	asymptomatic household contacts cases. Randomized within 96 hours e 1 st index case. tients	RT-qPCR confirmed COVII Outcome: Cohort A primary analysis 7.8%, 81% RRR in the tre Cohort B primary analysis	bjects who developed symptomatic D-19 through Day 29. in seronegative (753-752): 1.5% vs eatment group vs placebo in seronegative (100-104): 29% vs on in the treatment group vs placebo
Tixagevimab/Cilgavimab	Pre-exposure prophylaxis of COVII adolescents	D-19 in adults and	300+300 mg IM

Pre- and post-exposure prophylaxis

Product	Indication		Posology
Casirivimab/Imdevimab	Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg		 Post-exp: 600+600 mg IV/SC Pre-exp: 600+600 mg IV/SC, 300+300 mg q4w
	asymptomatic household contacts cases. Randomized within 96 hours le 1 st index case. tients	RT-qPCR confirmed COVII Outcome: Cohort A primary analysis 7.8%, 81% RRR in the tre Cohort B primary analysis	bjects who developed symptomatic D-19 through Day 29. in seronegative (753-752): 1.5% vs eatment group vs placebo in seronegative (100-104): 29% vs on in the treatment group vs placebo
Tixagevimab/Cilgavimab	Pre-exposure prophylaxis of COVII adolescents	D-19 in adults and	300+300 mg IM
active immunisation or at h	0 IM vs Placebo als at risk of inadequate response to igher risk of infection. SARS-CoV-2 ve individuals were excluded.	illness (COVID-19) throug Outcome: Primary analysis on PCR r	CoV-2 RT-PCR-positive symptomatic gh Day 183 negative at baseline (3441-1731): in the treatment group vs placebo

Treatment (1/3)

Medicine		Posology
Regdanvimab	Treatment of adults with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	40 mg/kg IV
Casirivimab/Imdevimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	600+600 mg IV/SC

Treatment (1/3)

Medicine			Posology
Regdanvimab	Treatment of adults with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		40 mg/kg IV
Intervention: Reg 40mg/Kg vs Placebohospitalisation, oxygen thPopulation: adult, symptomatic, SARS-CoV-2 confirmedhospitalisation, oxygen thpatients, <=7 days of symptoms, mild-moderate infection, not		ient at increased risk (66.9%, 446 vs	
Casirivimab/Imdevimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		600+600 mg IV/SC

Treatment (1/3)

Medicine			Posology
Regdanvimab	Treatment of adults with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		40 mg/kg IV
Intervention: Reg 40mg/Kg vs Placebo Population : adult, symptomatic, SARS-CoV-2 confirmed patients, <=7 days of symptoms, mild-moderate infection, not requiring oxygen Sat 94%, not hospitalized, unvaccinated Outcome: Primary analysis in all patients		ient at increased risk (66.9%, 446 vs	
Casirivimab/Imdevimab	434): 3.1% vs 11.1%, RR Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		600+600 mg IV/SC
mild-moderate severity, no	, 1200-1200 IV, placebo SARS-CoV-2 confirmed patients, t hospitalised, unvaccinated. <=7 one risk factor for severe disease.	hospitalisation or all cause Outcome: mFAS (PCR+, one risk fac 1200 mg (1192-1193): 0.	tor and seronegative):

Treatment (2/3)

Medicine		Posology
Sotrovimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	500 mg IV
Tixagevimab/Cilgavimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	300+300 mg IM

Treatment (2/3)

Medicine			Posology
Sotrovimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		500 mg IV
COMET-ICE Intervention: S 500 mg IV vs PlaceboPEP: P >24 ho any cau patients, ≤ 5 days symptomatic, SARS-CoV-2 confirmed patients, ≤ 5 days symptoms, Sat >=94%, ≥ 1 risk factors. Unvaccinated.OutcomOutcomOutcom			D-19 as defined by hospitalisation for agement of any illness or death from 1% 1% vs 6%, RRR 79%
Tixagevimab/Cilgavimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		300+300 mg IM

Treatment (2/3)

Medicine			Posology
Sotrovimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		500 mg IV
	$500 \text{ mg IV vs Placebo}$ >24 hours for acute mana, symptomatic, SARS-CoV-2 confirmedany cause (day 29)symptoms, Sat >=94%, ≥ 1 risk factors.Outcome:		D-19 as defined by hospitalisation for agement of any illness or death from 1% vs 6%, RRR 79%
Tixagevimab/Cilgavimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		300+300 mg IM
mild-moderate severity, no	SARS-CoV-2 confirmed patients, t hospitalised, unvaccinated. \leq 7 0% were to meet the protocol	cause by Day 29.	severe COVID-19 or death from any ot hosp, <7 days)(407-415) : 4.4%

Treatment (3/3)

Medicine		Posology
Bamlanivimab and Bamlanivimab/Etesevimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	700 mg Bam IV 700 mg Bam + 1400 mg Ete IV

Treatment (3/3)

Medicine			Posology
Bamlanivimab and Bamlanivimab/Etesevimab	Treatment of adults and adolescents with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		700 mg Bam IV 700 mg Bam + 1400 mg Ete IV
BLAZE-1 phase 3 Intervention: B/E 2800+2800 vs placebo arm, B/E 700+1400 vs placebo arm		PEP: COVID-19 related hospitalization (>24 h acute care) and death from any cause (day 29)	

Population: symptomatic, SARS-CoV-2 confirmed patients, ≤ 3 days from diagnostic sample, not requiring oxygen, mild to moderate disease, high risk of progression

Outcome:

Analysis 2800+2800 arm (518 vs 517): 2% vs 7%, RRR 70% Analysis 700+1400 arm(511 vs 776): 0.8% vs 6.8%, RRR 88%



Study	Enrolment period	Viral variants	Study sites
COV-2069 (Ronapreve proph)	July 2020 – March 2021	-	Brazil, Chile, Greece, Israel, Mexico, Moldova, US
COMET-ICE (Sotrovimab)	August 2020-April 2021	Wildtype, Alpha and Epsilon	US, Brazil, Spain, Canada, Peru
BLAZE-1 phase 2 (Bamlan/Etesev)	Sept 2020 - Dec 2020	-	US
PROVENT (Evusheld proph)	Nov 2020 – March 2021	Alpha, Beta, Gamma and Delta	US, UK, Belgium, France, Spain
TACKLE (Evusheld treat)	Jan 2021 - July 2021	Alpha, Beta, Gamma and Delta	Argentina, Brazil, Czech Republic, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Spain, UK, Ukraine, US
CT-P59 part 2 (Regkirona)	Jan 2021 – May 2021	Wild type and Alpha	Hungary, Ireland, Italy, Mexico, North Macedonia, Peru, Poland, Republic of Korea, Republic of Moldavia, Romania, Serbia, Spain, Ukraine, US
COV-2067 (Ronapreve treat)	Jan 2021 – Feb 2021	-	Mexico, Romania, US

Conclusions (1/2):

 Clinical studies have demonstrated efficacy of monoclonal antibodies only in the context of prophylaxis and for the treatment of patients in the early stage of the disease (not requiring supplemental oxygen)

• **Primary endpoints:**

- Prophylaxis: Proportion of symptomatic confirmed infection
- Treatment: Disease progression, COVID-19 related hospitalizations, all cause deaths.






Conclusions (2/2)

- Studies performed prevalently in high-risk patients when placebo-controlled designs could still be conducted.
- Efficacy shown in **unvaccinated and/or seronegative** patients.
- Available data do not allow to directly establish efficacy in several underrepresented subpopulations (immunosuppressed, elderly). Very limited evidence on pregnant women, breastfeeding, adolescents and children.
- Efficacy shown against **viral variants no longer circulating** and that could be potently neutralized by the monoclonal antibodies.

- —— Ancestral strain: SARS-CoV-2/UT-NC002-1T/Human/2020/Tokyo
- Omicron BA.2: hCoV-19/Japan/UT-NCD1288-2N/2022
- —— Omicron BA.5: hCoV-19/Japan/TY41-702/2022

A Neutralizing Activity of Monoclonal Antibodies



Omicron BQ.1.1: hCoV-19/Japan/TY41-796/2022

Omicron XBB: hCoV-19/Japan/TY41-795/2022

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB (nejm.org)

EUROPEAN MEDICINES AGENCY



9 December 2022 EMA/931457/2022 Emergency Task Force

ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants of concern

ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2 European Medicines Agency (europa.eu)

tors by the European Medicines Agency



Any questions?

Further information

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000 Send us a question Go to www.ema.europa.eu/contact



Classified as internal/staff & contractors by the European Medicines Agency